Piravir
(favipiravir), as a new broad-spectrum anti-RNA virus drug, was
approved for marketing in Japan in March 2014 for antiviral treatment of
influenza A and B.
| Product Name: | favipiravir |
| MF: | C5H4FN3O2 |
| MW: | 157.1025632 |
| CAS: | 259793-96-9 |
| Assay: | 99% |
Specification
| Items | Specifications |
| Appearance | White or off white or yellowish powder |
| Identification | The HPLC spectrum of the sample must be concordant with Test standard |
| The IR absorption spectrum of the sample must be concordant with Test standard |
| Related substances | Individual impurity substance ≤0.2% |
| Total impurity substance ≤0.5% |
| Water | NMT 0.5% |
| Residue on Ignition | NMT 0.2% |
| Heavy metals | NMT 20ppm |
| Assay | on the anhydrous base, should be 98.0% ~102.0% |
Application area

Favipiravir
can be used for antiviral treatment of influenza A and B.Studies have
shown that in addition to influenza viruses, the drug also exhibits good
antiviral activity against various RNA viruses, such as Ebola virus,
sand virus, Bunia virus, rabies virus, etc.
Packaging & Shipping



Our Services
